Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
The current price of CINGW is $0.03 USD — it has increased by +1.98% in the past 24 hours. Watch Cingulate stock price performance more closely on the chart.
What is Cingulate stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cingulate stocks are traded under the ticker CINGW.
Is Cingulate stock price growing?▼
CINGW stock has fallen by -7.49% compared to the previous week, the month change is a -33.97% fall, over the last year Cingulate has showed a -48.5% decrease.
What is Cingulate market cap?▼
Today Cingulate has the market capitalization of 208,791.3
When is the next Cingulate earnings date?▼
Cingulate is going to release the next earnings report on May 13, 2026.
What were Cingulate earnings last quarter?▼
CINGW earnings for the last quarter are -0.96 USD per share, whereas the estimation was -0.63 USD resulting in a -51.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cingulate revenue for the last year?▼
Cingulate revenue for the last year amounts to 0 USD.
What is Cingulate net income for the last year?▼
CINGW net income for the last year is -31.09M USD.
How many employees does Cingulate have?▼
As of April 02, 2026, the company has 13 employees.
In which sector is Cingulate located?▼
Cingulate operates in the Health Care sector.
When did Cingulate complete a stock split?▼
The last stock split for Cingulate was on November 30, 2023 with a ratio of 1:20.